NCT05574101
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
See at-risk trials from Memorial Sloan Kettering Cancer Center
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 14 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 6, 2026 to Oct 6, 2027
- Eligibility criteria expanded, about 40 words
- Notable Primary endpoint revisedv23
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 13 of 13 sites
- Minor Site details revised at 1 of 13 sitesv13
- Minor Study sites: 14 to 13v12
Show 8 earlier versionsHide 8 earlier versions
- Minor Site details revised at 1 of 14 sitesv10
- Minor Site details revised at 1 of 14 sitesv9
- Notable Eligibility criteria expanded, about 17 wordsv7
- Notable Primary and study completion dates: Oct 6, 2024 to Oct 6, 2026
- Site details revised at 1 of 14 sites
- Minor Site details revised at 1 of 14 sitesv5
- Minor Study sites: 12 to 14v4
- Minor Site details revised at 1 of 12 sitesv3
- Minor Study sites: 13 to 12v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Event Free Survival
Timeframe: 18 months
Arms and interventions
Participants with locally advanced, unresectable cutaneous squamous cell carcinoma/CSCCExperimental
Participants have locally advanced, unresectable cutaneous squamous cell carcinoma/CSCC
Drugs: Cemiplimab
Radiation: Radiotherapy
Sites
13 sites in 1 country